Search PubMed⌕ Search

Biomedical subjects

K Friese

Publications and source records attributed to K Friese.

114 records · Page 7Linked to original sources
PubMedDate not supplied

Immunohistochemical expression of steroid receptors and glycodelin A in isolated proliferative human endometrial glandular cells after stimulation with tamoxifen and phytoestrogens (genistein and daidzein).

INTRODUCTION: The aims of this study were an evaluation of the distribution patterns of steroid hormone receptors (ER, PR) and glycodelin A (GdA) expression of proliferative endometrial glandular cells after stimulation with tamoxifen (TAM) and phytoestrogens (PE) (genistein, daidzein). MATERIALS AND METHODS: Human endometrium was obtained from 4 premenopausal women. Glands were stimulated after isolation with single doses of TAM, genistein and daizein (0.1, 1 and 10 mumol/l) and characterised with ER, PR and GdA after 9 days of culture. RESULTS: ER showed a significant decline with the highest TAM and genistein concentration (p < 0.05), whereas PR increased significantly with TAM and genistein concentrations of 1 mumol/l and 10 mumol/l (p < 0.05). GdA did not show any significant expression under TAM and genistein stimulation. Stimulation with daidzein resulted in no statistically relevant alterations in ER, whereas the PR significantly increased with all three concentrations (p < 0.05) and GdA also showed a significant increase with 1 mumol/l (p < 0.05). DISCUSSION: TAM showed anti-estrogenic properties in premenopausal endometrium. PE showed a similar ER, PR expression pattern as TAM, so therefore PE (genistein and daidzein) could also act as antiestrogens. GdA marked a cell transformation from proliferative to secretory status or the antiestrogen effects of TAM and PE.

Adult↗
PubMedDate not supplied

Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR).

Human endometrium expresses estrogen (ER) and progesterone (PR) receptors, which are related to autocrine and paracrine processes that respond to estrogen and progesterone. The ER and PR expression and distribution pattern may play an important role in endometrial function and pathogenesis. The aim of this study was to evaluate the distribution pattern of ER-alpha, ER-beta and PR in normal (n=15) and malignant (n=11) human endometrial tissue. Commercially available monoclonal antibodies against ER-alpha, ER-beta and PR were used. The distribution of the steroid receptors was evaluated using the IRS-score and the Mann-Whitney rank-sum test was used to compare the means. Correlation was assessed with the Spearman factor and linear regression analysis. ER-alpha, ER-beta and PR declined significantly (p <0.05) in normal glandular epithelium from proliferative to late secretory phase, although the staining intensity of ER-beta was lower than that of ER-alpha. ER-alpha, ER-beta and PR were also expressed in malignant endometrial tissue. A significant correlation by regression analysis of ER-alpha and ER-beta was demonstrated, showing a dependence in the expression of these steroid receptors. The ER-alpha/ER-beta ratio decreased significantly from normal to malignant endometrial tissue (p<0.05), while the ER-beta/ER-alpha ratio showed statistical differences within normal endometrial tissue. These results showed the presence of steroid receptors in normal and malignant human endometrium, indicating a significant role in endometrial physiology and malignant transformation.

Endometrial Neoplasms↗
PubMedDate not supplied

Expression of inhibin/activin subunits, sialyl-lewis A (CA 19-9, sLea) and sialyl-Lewis X (sLex) carbohydrate antigens in a hydatidiform mole with persistent polymorphic trophoblastic hyperplasia.

UNLABELLED: The persistence of polymorphic trophoblastic hyperplasia in a hydatidiform mole is an extremely rare condition. Its early diagnosis is essential since such cases can transform into invasive tumours. MATERIALS AND METHODS: The paraffin-embedded biopsies were routinely stained with HE. Immunohistochemical staining reactions were performed with monoclonal antibodies against inhibin-alpha, inhibin-betaA and inhibin-betaB subunits. Additional immunohistochemical reaction was performed with, Sialyl-Lewis A and Sialyl-Lewis X and glycodelin. RESULTS: Large villi and hydatidiform villi with ranging syncyctio- and cytotrophoblasts were seen. Intervillous proliferating trophoblasts showed cell- and nuclear polymorphy with invasion of the myometrium wall. The immunohistochemistry exhibited strong positivity for inhibin-alpha, inhibin-betaA and inhibin-betaB subunits in trophoblastic tissue, while the decidua was negative. Sialyl-Lewis A and Sialyl-Lewis X showed no or minimal focal immunohistochemical reaction. CONCLUSION: A complete hydatidiform mole with hyperplasia and proliferation presents a high risk of developing a persistent (eventually metastatic) trophoblastic disorder and, in up to 15% of the cases, an invasive mole. In 2.5% of the cases it can transform into a choriocarcinoma. Since the inhibin/activin subunits reacted positively with trophoblastic tissue, they might be a useful diagnostic marker for hydatidiform mole with persistence of polymorphic trophoblastic hyperplasia.

Activins↗
PubMedDate not supplied

Study participation improves treatment strategies and individual patient care in participating centers.

BACKGROUND: The ADEBAR study is a prospective multicenter Phase III trial to examine whether high-risk breast cancer patients > or =4 involved axillary lymph nodes) benefit from a sequential anthracycline-docetaxel regimen compared to standard chemotherapy with anthracyclines. With a median recruitment of 33 patients per month at 198 actively-recruiting centers, the ADEBAR study was the best recruiting study in Germany until the end of the trial. MATERIALS AND METHODS: A standardized questionnaire was sent to all participating centers in order to determine the extent to which treatment strategies and patient care are affected by participation in the ADEBAR study. The questionnaire covered 5 areas of interest: previous inclusion of patients at the same tumor stage in other studies, the type of chemotherapy received by comparable patients previously outside the study, change in the intensity of medical care since participating in the ADEBAR study, the information gained through participation in the study and changes in the overall quality of medical care. RESULTS: 51.0% (n=98) of the questionnaires were returned, from which 3 were excluded from the analysis due to being incomplete. In the year preceding the ADEBAR study, 63.2% of participating centers had not entered their high-risk patients into a clinical trial. Before participating in the ADEBAR protocol, 44.2% of patients with the same indication had received inadequate therapy by today's standards, such as CMF, EC/CMF or 4x EC. 59.0% of the centers noted an increase in the intensity of patient care as a result of participation in the study, independent of the care provided purely because of the study. By being part of a research network, with a regular flow of information via newsletters, study meetings and the like, 80.0% noted an improvement in their professional knowledge in the field of breast cancer. Moreover, 31.6% of the centers reported an improvement in the overall quality of their patient care since the start of the trial. CONCLUSION: The results of the survey demonstrate that both physicians and patients benefit from participation in clinical trials as this is associated with optimized decision-making as regards therapy and patient care.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

[Degree of placental maturity and histopathologic finding: clinical prospective studies of a sample of term births and premature births].

By analogy with Grannum et al.'s sonographic classification of the placenta (1979), macroscopic observation of the cut surfaces of the afterbirth enables the extent of placental segmentation to be determined and macroscopic maturity to be established in accordance with sonographic findings. Out of a total of 767 clinically-prospectively documented obstetrical cases, 674 were identified as term births and 93 as premature. For the purposes of comparison they were subdivided into two groups: term births with stage 0 to II and stage III maturity; and premature births with stage 0 to II and stage III maturity. Proceeding from this morphological classification and grouping, the clinical data, such as age of the mother, parity, gravidity, diseases during pregnancy, premature labour, type of delivery, fetal outcome, and biometric data of the newborn, as well as histologic findings regarding villous maturity, were recorded and statistically analyzed. The findings revealed no significant differences between term births with stage III maturity and those in the control group of placentas with stage 0 to II maturity and the same gestation time. Therefore, stage III maturity at term corresponds chronopathologically to a normal temporal development of fetomaternal flow units of the mature human placenta at term and does not imply any perinatological risk. Histopathologically, placentas with stage III maturity manifest a significantly advanced degree of villous maturity, with lower mean placental weight as the morphological correlate to threshold placental function, which is reflected in the clinical data of perinatological complications. Therefore, premature detection of a stage III placenta before term indicates a risk that should be kept in mind in the overall concept of prenatal monitoring parameters.

Chorionic Villi↗